HBL Portfolio Company Tolarex to Commence Phase I/IIa Trial of a Treatment for GVHD

Hadasit Bio Holdings Ltd portfolio company, announced today that it has received approval by the Ministry of Health of Israel to begin a phase I/IIa clinical trial of its treatment for graft-versus-host disease .

This entry was posted on poniedziałek, Kwiecień 20th, 2009 at 14:00 and is filed under Bez kategorii. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.

2 Responses to “HBL Portfolio Company Tolarex to Commence Phase I/IIa Trial of a Treatment for GVHD”

  1. Ольга Says:
    Kwiecień 6th, 2010 at 02:43

    Спасибо…

    Незнаю…

  2. WALLACE Says:
    Lipiec 20th, 2010 at 19:08


    Medicamentspot.com. Canadian Health&Care.No prescription online pharmacy.Special Internet Prices.Best quality drugs. High quality pills. Order drugs online…

    Buy:Zovirax.Retin-A.Zyban.Human Growth Hormone.100% Pure Okinawan Coral Calcium.Accutane.Prednisolone.Petcam (Metacam) Oral Suspension.Nexium.Arimidex.Valtrex.Actos.Lumigan.Prevacid.Mega Hoodia.Synthroid….